An argument that all prerandomized clinical trials are unethical

Area of Science:

• Clinical Trials Methodology
• Medical Ethics

Background:

• Randomized controlled trials (RCTs) often face slow patient accrual, impacting completion rates.
• Prerandomization designs have been proposed to accelerate enrollment in clinical studies.
• Ethical concerns regarding prerandomization have been previously raised by Ellenberg (1984).

Purpose of the Study:

• To critically evaluate the ethical implications of converting conventionally randomized studies to a prerandomized design.
• To determine whether prerandomization is inherently unethical or simply unnecessary.

Main Methods:

• The study employs a logical argumentation approach based on patient treatment preferences.
• It analyzes scenarios where patients have or do not have a preference for treatment arms.
• Ethical principles of informed consent, patient deceit, and autonomy are central to the analysis.

Main Results:

• If patients prefer a treatment, ethical prerandomization will fail, similar to conventional randomization.
• If prerandomization succeeds when patients have a preference, it implies unethical conduct.
• If patients have no preference, prerandomization offers no advantage over conventional randomization, rendering it unnecessary.

Conclusions:

• Prerandomization is deemed either unethical or unnecessary based on the analysis of patient preferences.
• The potential benefits of increased accrual must be weighed against the ethical compromises involved.
• The paper concludes that prerandomization is fundamentally flawed and should be avoided.